SCHEMBL2986370

SCHEMBL2986370

Oc1cccc(-c2nc3ccccn3c2NCc2cccc(Cl)c2)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 2/20 0.63
SENP8 Q96LD8 2/20 0.63
SENP7 Q9BQF6 2/20 0.63
SENP6 Q9GZR1 2/20 0.63
L3MBTL1 Q9Y468 2/20 0.63
NR1H4 Q96RI1 3/20 0.58
PLAU P00749 5/20 0.56
GAA P10253 6/20 0.54
KDM4E B2RXH2 5/20 0.54
ALDH1A1 P00352 5/20 0.54
MAPT P10636 5/20 0.54
HPGD P15428 4/20 0.54
NPSR1 Q6W5P4 2/20 0.54
TSHR P16473 1/20 0.54
MAPK1 P28482 1/20 0.54
HSD17B10 Q99714 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2977653 0.90 CASP3 (0.67) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL2989998 0.87 NR1H4 (0.66) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL2977931 0.87 PLAU (0.68) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL2989783 0.85 NR1H4 (0.63) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL2988118 0.84 L3MBTL1 (0.56) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL2979969 0.84 KDM4E (0.66) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL2985937 0.84 L3MBTL1 (0.67) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL20889506 0.81 CASP3 (0.54) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL20889496 0.80 SALL4 (0.79) CASP3SENP8SENP7SENP6L3MBTL1
SCHEMBL2984142 0.80 L3MBTL1 (0.56) CASP3SENP8SENP7SENP6L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100173930-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-07-08 US claimed
WO-2008016648-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-02-07 WO claimed
US-20100173930-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-07-08 US disclosed
WO-2008016648-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173930-A1 Certain Chemical Entities, Compositions and Methods TNNC1, TNNI3, TNNT2 CASP3 2997/4885SENP8 2710/4885SENP7 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.